Abstract
It is known that nitric oxide (NO) exerts numerous physiological activities in mammals and it is considered a key mediator in many skin disorders. NO is synthesized in human skin cells where it regulates diverse physiological mechanisms such as dermal blood flow, wound healing, skin pigmentation, and aging. The great challenge of NO-based therapies is to preserve the biological activity of this ephemeral free radical. To this end, new biomaterials have been emerging as platforms for NO release for diverse biomedical applications. This review will discuss the new strategies for releasing/generating controlled amounts of NO for several dermatological applications through the use of nanotechnology.
Keywords: Nitric oxide, nanoparticles, skin, wound healing, antibacterial, topical applications
Current Nanoscience
Title:Nanotechnology Allied to Nitric Oxide Release Materials for Dermatological Applications
Volume: 8 Issue: 4
Author(s): Amedea B. Seabra and Nelson Duran
Affiliation:
Keywords: Nitric oxide, nanoparticles, skin, wound healing, antibacterial, topical applications
Abstract: It is known that nitric oxide (NO) exerts numerous physiological activities in mammals and it is considered a key mediator in many skin disorders. NO is synthesized in human skin cells where it regulates diverse physiological mechanisms such as dermal blood flow, wound healing, skin pigmentation, and aging. The great challenge of NO-based therapies is to preserve the biological activity of this ephemeral free radical. To this end, new biomaterials have been emerging as platforms for NO release for diverse biomedical applications. This review will discuss the new strategies for releasing/generating controlled amounts of NO for several dermatological applications through the use of nanotechnology.
Export Options
About this article
Cite this article as:
B. Seabra Amedea and Duran Nelson, Nanotechnology Allied to Nitric Oxide Release Materials for Dermatological Applications, Current Nanoscience 2012; 8 (4) . https://dx.doi.org/10.2174/157341312801784159
DOI https://dx.doi.org/10.2174/157341312801784159 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Current Drug Targets Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Profiling of Autophagy-Associated microRNAs in the Osteosarcoma Cell Line of U2OS
Anti-Cancer Agents in Medicinal Chemistry The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Patent Selections
Recent Patents on Mechanical Engineering Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Applied Proteomics in Companion Animal Medicine
Current Proteomics Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
Current Radiopharmaceuticals Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Anticancer Potential of Doxorubicin in Combination with Green-Synthesized Silver Nanoparticle and its Cytotoxicity Effects on Cardio-Myoblast Normal Cells
Anti-Cancer Agents in Medicinal Chemistry Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry